The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05C | Hypnotics and sedatives | |
| 4 | N05CM | Other hypnotics and sedatives | |
| 5 | N05CM18 | Dexmedetomidine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 1 mg |
| Active Ingredient | Description | |
|---|---|---|
| Dexmedetomidine |
Dexmedetomidine is a selective alpha-2 receptor agonist with a broad range of pharmacological properties. It has a sympatholytic effect through decrease of the release of noradrenaline in sympathetic nerve endings. The sedative effects are mediated through decreased firing of locus coeruleus, the predominant noradrenergic nucleus, situated in the brainstem. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DEXDOR Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| DEXISUN Concentrated solution for infusion | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| PRECEDEX Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
